Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of Claims
The amendments to the claims filed August 13, 2024 are acknowledged and entered. Claims 1-24 are pending.
Priority
This application claims benefit of 63/519,310 filed August 14, 2023.
Information Disclosure Statement
Acknowledgement is made of the Information Disclosure Statements filed on August 13 and November 14, 2024. All references have been considered except where marked with a strikethrough.
Specification
The specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any of the errors of which applicant may become aware of in the specification.
Election/Restriction
The requirement for restriction set forth July 24, 2026 has been reconsidered and is hereby withdrawn.
Allowable Subject Matter
Claims 2 and 4-7 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims, and if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph.
The following is a statement of reasons for the indication of allowable subject matter:
The closest reference to the instant claims is Dirk et al. (EP2248523 A1)(hereinafter “Dirk”). Dirk teaches use of 2,6-Bis(diethanolamino)-4,8-diheptamethyleneimino-pyrimido[5,4-d]pyrimidine (pictured below) in the therapeutic treatment of diabetes mellitus and metabolic syndrome (see claims 1 and 2). The difference between Dirk and the instant claims is that the instant claims require that the alkyl of formula (I) is not substituted with a hydroxy group. Dirk does not teach formula (I) of the claims. There is no teaching which would have motivated a person of ordinary skill in the art before the effective filing date of the instant application to selectively modify Dirk into the claimed invention with any reasonable expectation of success.
PNG
media_image1.png
412
672
media_image1.png
Greyscale
Claim Rejections - 35 USC § 112a
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claim 1, 3 and 8-24 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
MPEP 2163.04 states:
In rejecting a claim, the examiner must set forth express findings of fact regarding the above analysis which support the lack of written description conclusion. These findings should:
• (A) Identify the claim limitation at issue; and
• (B) Establish a prima facie case by providing reasons why a person skilled in the art at the time the application was filed would not have recognized that the inventor was in possession of the invention as claimed in view of the disclosure of the application as filed.
Analysis Prong A:
In the instant case, the limitation at issue is “diabetes” as recited in claim 1. The limitation is not defined in the specification and would be understood to include both type 1 and 2 diabetes. The claimed method thus embraces treatment of both type 1 and type 2 diabetes.
Analysis Prong B:
State of the prior art reference Pathak et al. (Endocrinology and Diabetes 2019, Vol 12, 1-13) teaches type 1 diabetes (T1D) is caused by autoimmune destruction of insulin-producing β cells located in the endocrine pancreas in areas known as islets of Langerhans. The current standard-of-care for T1D is exogenous insulin replacement therapy. Recent developments in this field include the hybrid closed-loop system for regulated insulin delivery and long-acting insulins. Clinical studies on prediction and prevention of diabetes-associated complications have demonstrated the importance of early treatment and glucose control for reducing the risk of developing diabetic complications. Transplantation of primary islets offers an effective approach for treating patients with T1D. However, this strategy is hampered by challenges such as the limited availability of islets, extensive death of islet cells, and poor vascular engraftment of islets post-transplantation (Abstract). Pathak teaches existing interventions include insulin replacement, cell transplantation, and efforts to preserve beta cells (e.g. through immune therapies)(see Table 2).
The state of the prior art thus appears to regard treatment of type 1 diabetes as being centered on replacement of insulin and methods of increasing insulin production (e.g. by cell transplantation). In the instant case, the claimed method has no reported effect on insulin production nor does it appear to increase insulin in a subject. Given the state of the prior art, a person skilled in the art would not recognize that Applicant was in possession of a method of treating diabetes as broadly as is claimed at the time the application was filed. This rejection could be overcome by amending the claims to recite “type-2 diabetes”. Support for this amendment can be found at [0135] of the specification.
Claim Rejections - 35 USC § 112b
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1-24 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The claims are indefinite for the reasons that follow:
Claim 1 recites a variable “L” (see
PNG
media_image2.png
36
280
media_image2.png
Greyscale
); however, the claim does not define L. The metes and bounds of formula (I) are therefore unclear. The claim should be amended to define L (see e.g. [0014]). Claims 8-24 depend from claim 1, include the limitation L, and are indefinite for the same reason.
Claims 1-24 include the limitation “isotopic variant”. This limitation is indefinite because the specification fails to provide any example of such variants or provide a general definition. The metes and bounds of “isotopic variant” are unclear.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to KEVIN MARTIN whose telephone number is (571)270-0917. The examiner can normally be reached Monday - Friday 8 am - 5 pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached on (571) 272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
November 4, 2026
/K.S.M./Examiner, Art Unit 1624
/BRUCK KIFLE/Primary Examiner, Art Unit 1624